NovoCure News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

23.03.22	Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer (Businesswire)
28.02.22	Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation (Businesswire)
24.02.22	Novocure’s General Counsel Resigns After 10 Years of Service (Businesswire)
24.02.22	New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response (Businesswire)
24.02.22	Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update (Businesswire)
23.02.22	Ausblick: NovoCure zieht Bilanz zum jüngsten Jahresviertel (finanzen.net)
09.02.22	Erste Schätzungen: NovoCure legt Zahlen zum jüngsten Quartal vor (finanzen.net)
10.01.22	Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update (Businesswire)
04.01.22	Novocure to Participate in the 40th Annual J.P. Morgan Healthcare Conference (Businesswire)
07.12.21	Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New Hampshire (Businesswire)
06.12.21	Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program (Businesswire)
26.10.21	Ausblick: NovoCure legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
13.10.21	Erste Schätzungen: NovoCure gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
27.07.21	Ausblick: NovoCure mit Zahlen zum abgelaufenen Quartal (finanzen.net)
14.07.21	Erste Schätzungen: NovoCure stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
01.07.21	Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer (Businesswire)
16.06.21	Novocure Initiates Usability Study for Flexible Torso Array (Businesswire)
25.05.21	Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma (Businesswire)
18.05.21	Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer (Businesswire)
30.04.21	NovoCure-Aktie: Das sind die Analysten-Einstufungen des vergangenen Monats (finanzen.net)
29.04.21	Novocure Reports First Quarter 2021 Financial Results and Provides Company Update (Businesswire)
27.04.21	Ausblick: NovoCure veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
22.04.21	Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer (Businesswire)
15.04.21	Novocure gibt neueste Entwicklungen in der zulassungsrelevanten Phase-3-Studie LUNAR zu Tumor Treating Fields bei nicht-kleinzelligem Lungenkarzinom bekannt (Businesswire)
14.04.21	Erste Schätzungen: NovoCure gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
13.04.21	Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer (Businesswire)
09.04.21	Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields (Businesswire)
01.04.21	Novocure to Report First Quarter 2021 Financial Results (Businesswire)
25.02.21	Novocure Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update (Businesswire)
23.02.21	Ausblick: NovoCure legt Quartalsergebnis vor (finanzen.net)
10.02.21	Erste Schätzungen: NovoCure stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
08.02.21	Novocure Announces Addition to Its Board of Directors (Businesswire)
11.01.21	Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update (Businesswire)
23.12.20	Novocure to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference (Businesswire)
14.12.20	Novocure meldet nationale Kostenübernahme in der Schweiz für Optune® in Kombination mit Temozolomid zur Behandlung von neu diagnostiziertem Glioblastom (Businesswire)
14.12.20	Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (Businesswire)
10.12.20	First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma (Businesswire)
25.11.20	Novocure to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference (Businesswire)
19.11.20	Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting (Businesswire)
16.11.20	Prüfungsausschuss beschliesst Erstattung medizinischer Leistungen für Behandlung mit Tumor-Therapie-Feldern in Deutschland (Businesswire)
11.11.20	Novocure Receives CE Mark for NovoTTF-100L™ System (Businesswire)
10.11.20	Novocure Announces Agenda for Virtual Research and Development Day (Businesswire)
09.11.20	Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks (Businesswire)
05.11.20	Novocure Announces Closing of $575 Million 0% Convertible Senior Notes Private Placement (Businesswire)
03.11.20	Novocure Prices $500 Million 0% Convertible Senior Notes Private Placement (Businesswire)
02.11.20	Novocure Announces Proposed Private Placement of $500 Million of Convertible Senior Notes (Businesswire)
29.10.20	Novocure Reports Third Quarter 2020 Financial Results and Provides Company Update (Businesswire)
29.10.20	Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical Research (Businesswire)
27.10.20	Ausblick: NovoCure präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net)
13.10.20	Erste Schätzungen: NovoCure zieht Bilanz zum abgelaufenen Quartal (finanzen.net)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	121.00	2.07 %	K V
Swiss Re	129.85	1.21 %	K V
Lonza Grp	526.40	0.96 %	K V
Logitech Intl	71.46	0.62 %	K V
UBS Group	28.39	0.32 %	K V
Alcon	76.16	-0.68 %	K V
Swiss Life Hldg	728.20	-0.74 %	K V
Givaudan	3’892.00	-1.04 %	K V
Novartis	92.47	-1.29 %	K V
Sonova Hldg	306.30	-1.86 %	K V

Nachrichten zu NovoCure Limited

Aktien Top/Flop

Meistgelesene Nachrichten